In today's healthcare landscape, personalized treatments that cater to individual needs have been proven to be more effective. However, to ensure that these treatments are accessible and understandable to the general public, companies must take measures to make them so. That's why we back companies like Ani Biome, a metabolites-as-medicine startup that is dedicated to developing a personalized approach to improving gut microbiome health.
LongeVC managing partner Sergey Jakimov shared more details about our approach in the recent Longevity Technology article. He also discussed why we believe that Ani Biome's product is set for success.
You can read the whole piece here.
LongeVC managing partner Sergey Jakimov shared more details about our approach in the recent Longevity Technology article. He also discussed why we believe that Ani Biome's product is set for success.
You can read the whole piece here.